Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director | July 31, 2026 | August 04, 2026 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director | September 04, 2025 | September 08, 2025 |
| GridAI Technologies Corp.FWBI · Entity 7534 | Director | January 02, 2024 | January 04, 2024 |
| International Stem Cell CORPISCO.OB · Entity 8432 | Director | June 21, 2018 | June 25, 2018 |
| PaxMedica, Inc.PXMD · Entity 93047 | Director | March 12, 2024 | March 14, 2024 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director | December 12, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 10,000 · Balance 10,000 F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
GT Biopharma, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 62,500 |
Reported balance
After 2025-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-04 · Grant · Acquired 62,500 · Balance 62,500 F1: The options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are fully vested and exercisable.
GridAI Technologies Corp.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,937 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 19,633 · Balance 19,937 F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F2: Includes unvested RSUs.
International Stem Cell CORP
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,431 |
Reported balance
After 2018-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-21 · Grant · Acquired 4,328 · Balance 14,431 F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant.
PaxMedica, Inc.
Report date March 12, 2024 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,386 |
Reported balance
After 2024-03-12 transaction · row 1
1 source rowRow 1 · 2024-03-12 · Tax withholding · Disposed 992 · Balance 2,386 F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.
RELMADA THERAPEUTICS, INC.
Report date December 12, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12 | Direct | 164,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 164,000 · Balance 164,000 F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2021 Filed Jun 2, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 520 | $34.08 | $17,720.51 |
DisclosureSEC source: 0001213900-21-030571 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,430 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $33.84 to $34.54 per share, inclusive. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $38.22 | $114,647.10 |
DisclosureSEC source: 0001213900-21-024716 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,950 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $37.94 to $38.94 per share, inclusive. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 19,655 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001493152-21-010526 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,555 Underlying: Common Stock · 19,655 shares Expires 2031-05-03 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,691 | $35.04 | $59,253.15 |
DisclosureSEC source: 0001213900-21-020123 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $34.69 to $35.49 per share, inclusive. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,309 | $35.93 | $47,027.79 |
DisclosureSEC source: 0001213900-21-020123 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,641 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.80 to $36.12 per share, inclusive. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $33.87 | $101,617.80 |
DisclosureSEC source: 0001213900-21-012891 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,950 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $33.56 to $34.28 per share, inclusive. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 22:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,663 | $33.90 | $56,375.70 |
DisclosureSEC source: 0001213900-21-006210 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,950 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · balance_after: Sales prices range from $33.70 to $34.00 per share, inclusive. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 22:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,337 | $33.30 | $44,522.10 |
DisclosureSEC source: 0001213900-21-006210 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,613 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · balance_after: Sales prices range from $32.68 to $33.59 per share, inclusive. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:12 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 100,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001432 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in quarterly increments of 6.25%. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $32.11 | $96,341.70 |
DisclosureSEC source: 0001213900-21-000426 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,950 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $32.01 to $32.38. The average weighted price was $32.1139. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:40 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions (right to buy) · Derivative | 41,237 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001415889-21-000249 · form4-01062021_060119.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,237 Underlying: Common stock, par value $0.0001 per share · 41,237 shares Expires 2031-01-03 F1 · derivative.exercise_date: The options vest in equal quarterly installments on each of March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $35.74 | $107,219.10 |
DisclosureSEC source: 0001213900-20-040481 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,950 F2 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $34.54 to $36.065. The average weighted price was $35.7397. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2020 Filed Dec 2, 2020 21:01 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 21,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-040481 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,950 F1 · price: Gift to a family trust. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:03 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $30.29 | $90,863.70 |
DisclosureSEC source: 0001213900-20-034800 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,173 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $30.00 to $31.33. The average weighted price was $30.2879. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:02 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $37.99 | $113,955.60 |
DisclosureSEC source: 0001213900-20-029901 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,173 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $37.04 to $38.58. The average weighted price was $37.9852. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 20:36 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $34.74 | $104,206.80 |
DisclosureSEC source: 0001213900-20-025044 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,173 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $34.22 to $35.60. The average weighted price was $34.7356. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:13 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 26,362 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-20-022881 · ownership.xml · derivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,404 Underlying: Common Stock · 26,362 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:13 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Tax withholdingCommon Stock | 2,189 | $39.03 | $85,436.67 |
DisclosureSEC source: 0001213900-20-022881 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,173 F2 · shares: Reflects 2,189 shares withheld at the market price of $39.03 per share to fund the cashless exercise of 26,362 options owned by Mr. Casamento, which cashless exercise was approved in advance by the Board of Directors. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:13 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 26,362 | $3.24 | $85,412.88 |
DisclosureSEC source: 0001213900-20-022881 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 19:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $35.74 | $107,213.40 |
DisclosureSEC source: 0001213900-20-020143 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $35.40 to $36.69. The average weighted price was $35.7378. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 17:26 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,000 | $43.89 | $131,677.20 |
DisclosureSEC source: 0001213900-20-016524 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $43.03 to $44.63. The average weighted price was $43.8924. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 23:53 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 80,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001415889-20-000967 · form4-04072020_040421.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-04-06 F2 · price: Options issued in connection with the Reporting Person's service on the Issuer's Board of Directors. F1 · derivative.exercise_date: 25% of the options vest immediately, with the remainder vesting in equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020. Read SEC document |
| March 19, 2020 Filed Mar 24, 2020 00:15 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000846 · form4-03232020_050303.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · La Jolla Lenox Trust Disclosed balance after: 116,998 F1 · shares: On March 11, 2020, the Reporting Person transferred 9,000 shares of the Issuer's common stock to a family trust of which the Trustee is someone other than the Reporting Person. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. Read SEC document |
| March 19, 2020 Filed Mar 24, 2020 00:15 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000846 · form4-03232020_050303.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,998 F1 · shares: On March 11, 2020, the Reporting Person transferred 9,000 shares of the Issuer's common stock to a family trust of which the Trustee is someone other than the Reporting Person. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. Read SEC document |
| March 19, 2020 Filed Feb 16, 2021 13:59 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GiftCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-003826 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,420 Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 21,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-006781 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 21,484 F1 · ownership.nature: Represents shares of common stock held by a family trust. Mr. Casamento disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that Mr. Casamento is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 20:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 21,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-006781 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 27,400 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001493152-20-004058 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2030-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 20:10 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 8,414 | $1.04 | $8,750.56 |
DisclosureSEC source: 0001415889-20-000739 · form4-03132020_040311.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,998 F3 · shares: Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019. F4 · price: Based on the stock price at December 31, 2019 at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 20:10 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 14,584 | $0.60 | $8,750.40 |
DisclosureSEC source: 0001415889-20-000739 · form4-03132020_040311.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,584 F1 · shares: Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019. F2 · price: Based on the stock price at September 30, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:11 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | $1.04 | $7,800.00 |
DisclosureSEC source: 0001415889-20-000046 · form4-01032020_010128.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 21,094 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · derivative · entry 6 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,406 Underlying: Common Stock · 2,388 shares Expires 2019-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 46,484 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · derivative · entry 5 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,766 Underlying: Common Stock · 3,706 shares Expires 2019-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Tax withholdingCommon Stock | 2,388 | $40.64 | $97,048.32 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · nonDerivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,484 F2 · shares: Reflects 2,388 shares withheld at the market price of $40.64 per share to fund the cashless exercise of 21,094 options owned by Mr. Casamento, which cashless exercise was approved by the Board of Directors. F3 · balance_after: The shares of common stock held by Mr. Casamento remain subject to the terms of the Lock-Up Agreement, dated November 21, 2019, between Mr. Casamento and Jefferies LLC, as representative of the several underwriters listed on Schedule A to the Underwriting Agreement, dated December 3, 2019, by and among Jefferies LLC, SVB Leerink LLC and Relmada Therapeutics, Inc. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Tax withholdingCommon Stock | 3,706 | $40.64 | $150,611.84 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,872 F1 · shares: Reflects 3,706 shares withheld at the market price of $40.64 per share to fund the cashless exercise of 46,484 options owned by Mr. Casamento, which cashless exercise was approved by the Board of Directors. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 21,094 | $4.60 | $97,032.40 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 46,484 | $3.24 | $150,608.16 |
DisclosureSEC source: 0001213900-19-027115 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:54 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 100,000 | $43.47 Strike: $43.47 | $4,347,000.00 |
DisclosureSEC source: 0001213900-19-026852 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 18:27 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon | 7,500 | $0.60 | $4,500.00 |
DisclosureSEC source: 0001415889-19-001128 · form4-10012019_111009.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,500 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:17 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 3,500 | $6.11 | $21,369.95 |
DisclosureSEC source: 0001209191-19-045498 · doc4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,920 F1 · price: The range of purchase prices paid is $6.10 to $6.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 21:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 500,000 | $2.20 Strike: $2.20 | $1,100,000.00 |
DisclosureSEC source: 0001213900-19-014039 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 22:41 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon | 7,500 | $1.70 | $12,750.00 |
DisclosureSEC source: 0001415889-19-000816 · form4-07022019_030701.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending June 30, 2019. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:50 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000744 · form4-06172019_060631.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,500 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors. Read SEC document |
| June 13, 2019 Filed Jun 22, 2019 00:10 UTC Amendment | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 30,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-19-000788 · form4a-06212019_050657.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2024-06-13 F1 · derivative.exercise_date: Options will vest in quarterly installments over a one-year period beginning on June 30, 2019. Read SEC document |
| March 31, 2019 Filed Apr 30, 2019 00:24 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | $2.42 | $18,150.00 |
DisclosureSEC source: 0001415889-19-000487 · form4-04292019_050423.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending March 31, 2019. Read SEC document |
| February 20, 2019 Filed Mar 8, 2019 21:33 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001209191-19-018114 · doc4.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-02-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:58 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | $1.29 | $9,675.00 |
DisclosureSEC source: 0001415889-19-000010 · form4-01022019_020116.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2018. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:58 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | PurchaseCommon Stock | 9,000 | $1.41 | $12,690.00 |
DisclosureSEC source: 0001415889-19-000010 · form4-01022019_020116.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 21:53 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 450,000 | $1.15 Strike: $1.15 | $517,500.00 |
DisclosureSEC source: 0001213900-18-017633 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-12-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 00:24 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | ConversionSeries A Convertible Preferred Stock · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058827 · doc4.xml · derivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.